BridgeMD
New treatment option for Periodontitis
Official title Polynucleotide + Hyaluronic Acid Gel With Xenogeneic Graft for Intrabony Periodontal Defects
ClinicalTrials.gov ID: NCT07522684
What this study is testing
- What it's testing
- Over the last 30 years, the prevalence of periodontitis (PE) has increased substantially, including among younger populations, highlighting the need to improve the management of this condition as a chronic disease and to develop techniques that favor its control and stability in the short and long term. After non-surgical periodontal therapy (NSPT), the first phase of PE treatment, residual periodontal pockets may persist, often associated with intraosseous defects, which compromise the tooth's prognosis and are associated with disease progression and increased treatment complexity.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- ≥ 18 years of age;
- diagnosis of periodontitis stage III or IV, grade B or C (Chapple et al., 2018; Papapanou et al., 2018);
- full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) of ≤ 20%;
- presence of a 2- or 3-wall intrabony defect with a depth ≥ 3 mm and probing depth and clinical attachment level ≥ 5 mm in the interproximal region of...
- pulp vitality or satisfactory endodontic treatment in the tooth to be treated;
You likely can't join if
- presence of furcation involvement associated with the intrabony defect;
- presence of systemic conditions that may affect the progression of periodontitis or the response to its treatment;
- long-term use of anti-inflammatory or immunosuppressive medications;
- use of antimicrobials within the last 6 months;
- continuous use of mouthwashes containing antimicrobial agents within the last 6 months;
- need for prophylactic antibiotic therapy for routine dental procedures;
See the full eligibility criteria
- ≥ 18 years of age;
- diagnosis of periodontitis stage III or IV, grade B or C (Chapple et al., 2018; Papapanou et al., 2018);
- full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) of ≤ 20%;
- presence of a 2- or 3-wall intrabony defect with a depth ≥ 3 mm and probing depth and clinical attachment level ≥ 5 mm in the interproximal region of a single- or multi-rooted tooth;
- pulp vitality or satisfactory endodontic treatment in the tooth to be treated;
- at least 1 mm of keratinized tissue on the buccal surface of the tooth to be treated.
- presence of furcation involvement associated with the intrabony defect;
- presence of systemic conditions that may affect the progression of periodontitis or the response to its treatment;
- long-term use of anti-inflammatory or immunosuppressive medications;
- use of antimicrobials within the last 6 months;
- continuous use of mouthwashes containing antimicrobial agents within the last 6 months;
- need for prophylactic antibiotic therapy for routine dental procedures;
- current or past tobacco use within the last 5 years;
- pregnancy;
- breastfeeding.
The study team makes the final eligibility decision.
Where it's taking place
- Ribeirão Preto, São Paulo, Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ribeirão Preto, São Paulo, Brazil. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.